FDA Approves Lytenava as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD – Outlook Theraputics
Outlook Therapeutics, Inc. announced that the FDA has approved Lytenava (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval establishes… read more.
